BriaCell Therapeutics Corp. has announced a collaboration with the Memorial Sloan Kettering Cancer Center (MSK) to advance its Bria-OTS+ immunotherapy platform aimed at treating breast cancer and other malignancies. This partnership will focus on the development and manufacturing of Bria-OTS+, particularly its Bria-BRES+ variant designed for breast cancer patients.
The collaboration was officially revealed on October 21, 2025, and marks a significant step in BriaCell”s efforts to accelerate clinical development. The partnership with MSK”s Therapeutics Accelerator Cohort program will facilitate the initial phases of a Phase 1 clinical trial, providing essential support in the areas of manufacturing, Investigational New Drug (IND) application processes, and clinical trial protocols.
The integration of BriaCell”s innovative therapeutic approach with MSK”s extensive expertise in cancer treatment signifies a strategic move to enhance patient outcomes. Dr. William V. Williams, President and CEO of BriaCell, expressed enthusiasm about working with MSK”s distinguished team of cancer specialists to address critical unmet needs in the treatment of metastatic breast cancer.
Dr. Miguel Lopez-Lago, Chief Scientific Officer at BriaCell, emphasized the honor of collaborating with MSK, highlighting the potential of the Bria-OTS+ platform to revolutionize cancer treatment and significantly improve the quality of life for patients through its unique therapeutic mechanisms.
Dr. Shanu Modi, a Breast Medical Oncologist at MSK, stated the importance of such collaborations in translating scientific innovations into viable treatment options for patients. This joint effort aims to bridge the gap between promising research and practical applications, ultimately benefiting those affected by cancer.
In summary, BriaCell”s collaboration with MSK is poised to enhance the clinical trajectory of its personalized off-the-shelf immunotherapy, with hopes of delivering transformative care to breast cancer patients and beyond.
For more information about BriaCell, visit briacell.com.
The MSK Therapeutics Accelerator program partners with biotechnology firms to expedite the development of innovative cancer therapies, leveraging MSK”s renowned clinical and scientific resources to improve cancer treatment methodologies.
As this collaboration unfolds, both organizations are committed to advancing the field of cancer therapy and addressing the pressing needs of patients worldwide.
